On August 17, Fuhong Hanlin announced that it has established a strategic cooperation with Sandoz, a global generic drug and biosimilar company, on up to 10 monoclonal and/or antibody-conjugated drug biosimilar products or ingredients, and signed a cooperation agreement on the choice of the first batch of 3 products and 1 product selected. In April 2025, the two sides reached an exclusive commercial cooperation on the ipimumab biosimilar drug HLX13 in 46 countries and regions, including Europe and the US. This cooperation is a further deepening on the basis of the existing biosimilar cooperation between the two sides in the field of oncology.

On August 17, Fuhong Hanlin announced that it has established a strategic cooperation with Sandoz, a global generic drug and biosimilar company, on up to 10 monoclonal and/or antibody-conjugated drug biosimilar products or ingredients, and signed a cooperation agreement on the choice of the first batch of 3 products and 1 product selected. In April 2025, the two sides reached an exclusive commercial cooperation on the ipimumab biosimilar drug HLX13 in 46 countries and regions, including Europe and the US. This cooperation is a further deepening on the basis of the existing biosimilar cooperation between the two sides in the field of oncology.